#USA #Miramar #DifGen #AVEVA #JKB-122

DifGen Pharmaceuticals and Aveva Drug Delivery Systems Collaborate for Immune Therapy Development

In a significant move within the pharmaceutical sector, DifGen Pharmaceuticals and Aveva Drug Delivery Systems have announced a strategic collaboration focusing on the development of a next-generation immune restoration therapy platform, known as JKB-122. This partnership also includes Biostax Corp (doing business as Attune Biotech), SGP Holdings, and Callan JMB, all aimed at advancing technology transfer and the development of critical immune therapies for various conditions, including Long COVID and autoimmune diseases.

Strategic Significance of the Collaboration

The primary aim of this partnership is to enhance the formulation and manufacturing of the JKB-122 platform. This platform is unique as it transitions from a single-indication development model into a broad-spectrum therapeutic approach capable of addressing multiple clinical indications with a unified Chemistry, Manufacturing, and Controls (CMC) and regulatory framework. This strategy is particularly beneficial as it aligns the requirements for diverse therapeutic developments under a single platform, thereby streamlining processes and enhancing efficiency.

As part of this collaboration, the technology transfer will allow for the seamless integration of Biostax's FDA-reviewed CMC program. This program consists of comprehensive manufacturing and formulation processes for multiple dosing strengths, enabling support for both immediate and sustained-release medications.

Current Clinical Development Programs

Currently, Biostax is advancing multiple clinical programs using the JKB-122 platform. Key indications include treatments for Long COVID (Post-Acute Sequelae of SARS-CoV-2/PASC), Autoimmune Hepatitis, and conditions such as MASLD and MASH. In addition to these programs, Biostax is preparing for the submission of Investigational New Drug (IND) applications targeting immune non-responders in HIV, chronic pain linked with immune dysfunction, and therapies for individuals experiencing failure in virologically effective HIV treatments.

Fast Track Designation & Phase Authorization

One of the most significant components of this collaboration is the lead program focused on Long COVID. This program has already been granted Fast Track designation and an Emergency Use Authorization (EUA) application has been filed with the FDA. The agency has conducted a review of the Phase 2b/3 protocol for this indication and provided preliminary approval, indicating that the proposed study can proceed. This kind of regulatory support is vital not only for the immediate success of the project but also for building momentum in drug development processes across various platforms.

Advanced Platform Formulation Strategies

DifGen and Aveva are committed to leading the development of platform formulations that cater to a range of clinical needs. Their strategy involves:

• - Immediate-release titration doses: Ranging from 0.05 mg to 5 mg, which facilitate gradual dosage adjustments for patients.
• - Maintenance dosing: Development of sustained-release formulations available in 10 mg and 35 mg doses, aimed at providing longer therapeutic effects.
• - Pediatric dosing initiatives: Adjusting formulations to meet the needs of younger patients while considering safety and efficacy.
• - Stability and shelf-life optimization: Ensuring medications maintain effectiveness over their intended shelf life.
• - U.S.-based GMP manufacturing: This guarantees that all products are manufactured in compliance with Good Manufacturing Practices, ensuring patient safety and product reliability.

This multifaceted formulation approach is designed to cater to a wide range of immune-mediated and chronic inflammatory conditions, demonstrating the versatility and potential reach of the JKB-122 platform.

Sustained-Release Formulation for MASLD/MASH

Under the FDA's 505(b)(2) regulatory pathway, DifGen is also working on sustained-release formulas targeting MASLD (Metabolic Dysfunction-associated Steatotic Liver Disease) and MASH (Metabolic Dysfunction-associated Steatotic Hepatitis). This pathway allows for the integration of existing safety data, which accelerates the development of these new formulations and treatment indications.

Independent Oversight & Compliance

To maintain high standards of quality and compliance, Callan JMB will oversee manufacturing, quality systems, and supply chain operations. This independent validation ensures adherence to federal requirements, including those set forth by agencies like BARDA and the Department of Defense. The emphasis on independent oversight highlights the commitment to maintaining consistent quality across all manufacturing levels, ultimately benefiting the patients receiving these therapies.

Executive Insights

The co-founders of DifGen Pharmaceuticals, Ramandeep Singh Jaj and Santhanakrishnan Srinivasan, expressed their excitement regarding this collaboration. They noted that this partnership would not only enhance the manufacturing and formulation development but also solidify their role in shaping the future of clinical programs built upon innovative therapeutic platforms.

Noreen Griffin, President of Biostax, echoed these sentiments, emphasizing the importance of this collaboration in transitioning from a focused development approach to a comprehensive platform capable of addressing various diseases driven by immune disorders.

Why Upstream Immune Restoration Matters

Understanding chronic diseases like Long COVID and autoimmune illnesses necessitates a shift in approach. Many of these conditions are believed to stem from underlying immune dysregulation rather than solely from the primary disease triggers. By focusing on restoring immune balance through upstream therapies such as JKB-122, these innovative platforms may offer effective treatments for a spectrum of diseases characterized by immune dysfunction—a particularly timely focus within the current landscape of disease management. By utilizing a single therapeutic and formulation infrastructure, this collaboration has the potential to enhance development efficiency, improve scalability in production, and increase patient access to life-changing therapies.

In sum, the collaboration among DifGen, Aveva, and their partners marks a significant step forward in immune therapy development, promising a new era of treatment possibilities for patients battling chronic conditions linked to immune disruption.